In the BioHarmony Drug Report Database

"Preview" Icon

Teriparatide

Bonsity, Forteo, Forsteo (teriparatide) is a protein pharmaceutical. Teriparatide was first approved as Bonsity on 2002-11-26. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis and postmenopausal osteoporosis. The pharmaceutical is active against parathyroid hormone/parathyroid hormone-related peptide receptor. In addition, it is known to target parathyroid hormone 2 receptor. Forteo’s patent is valid until 2025-03-25 (FDA).

 

Trade Name

 

Forsteo
 

Common Name

 

teriparatide
 

ChEMBL ID

 

CHEMBL525610
 

Indication

 

osteoporosis, postmenopausal osteoporosis
 

Drug Class

 

Peptides: parathyroid hormone related peptide

Image (chem structure or protein)

Teriparatide structure rendering